XBiotech Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
XBIT$1.97+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Operating activities | |||
| Net loss | $(38,531) | $(24,557) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation | 1,745 | 1,744 | |
| Foreign exchange loss (gain) | 5,529 | (1,893) | |
| Share-based compensation expense | 1,753 | 3,262 | |
| Changes in operating assets and liabilities: | |||
| Income tax receivable | (83) | 473 | |
| Accrued interest receivable | 160 | 356 | |
| Prepaid expenses and other current assets | (271) | (160) | |
| Accounts payable | (364) | 91 | |
| Accrued expenses | (877) | 1,895 | |
| Income tax payable | (24) | 123 | |
| Deferred tax liability | - | (59) | |
| Net cash used in operating activities | (30,963) | (18,725) | |
| Investing activities | |||
| Purchase of property and equipment | (1,304) | (362) | |
| Proceeds from maturity of interest bearing time deposits | - | 61,859 | |
| Net cash (used in) provided by investing activities | (1,304) | 61,497 | |
| Financing activities | |||
| Proceeds from convertible loan, related party | 10,000 | - | |
| Proceeds from convertible loan, third party | 250 | - | |
| Cash paid in tender offer | - | (14) | |
| Issuance of common stock under stock option plan | 200 | 5 | |
| Net cash provided by (used in) financing activities | 10,450 | (9) | |
| Effect of foreign exchange rate on cash and cash equivalents | (5,529) | (46) | |
| Net change in cash and cash equivalents | (27,346) | 42,717 | |
| Cash and cash equivalents, beginning of year | 200,023 | 157,306 | |
| Cash and cash equivalents, end of year | $172,677 | $200,023 | |
| Supplemental Information: | |||
| Accrued purchases of property and equipment | $70 | $19 | |
| Cash paid for interest | $400 | $ | - |
| Cash paid for income taxes | $85 | $141 | |
See accompanying notes to consolidated financial statements.
Notes to Consolidated Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.